Breaking Finance News

Tesaro Inc (NDAQ:TSRO) stock price target bumped up to $175.00, released a ratings update earlier today by Gabelli

Only yesterday Tesaro Inc (NDAQ:TSRO) traded 0.87% higher at $135.79. The company’s 50-day moving average is $130.46 and its two hundred day average is $149.15. With the last close down -25.01% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. Volume of trade was down over the average, with 800,674 shares of TSRO changing hands under the typical 1,253,190

Gabelli raised the target price of Tesaro Inc (NDAQ:TSRO) to $175.00 stating a potential upside of 0.29%.

Previously on 6/20/2017, Bank of America Corporation reported on Tesaro Inc (NDAQ:TSRO) upped the target price from $0.00 to $154.00. At the time, this indicated a possible upside of 0.11%.

Recent Performance Chart

Tesaro Inc (NDAQ:TSRO)

Tesaro Inc has 52 week low of $83.26 and a 52 week high of $192.94 and has a market cap of $0.

In addition to Gabelli reporting its target price, a total of 10 brokers have issued a report on the company. The average stock price target is $89.00 with 8 brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Tesaro Inc (NDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.